Applied Genetic (AGTC) Stock
AGTC is no longer traded. Applied Genetic was delisted from the Nasdaq in November 2022.
Prices on this page are historical; the last trade was November 30, 2022 at $0.39.
Applied Genetic stock price history
AGTC final trading statistics
- Final close
- $0.39
- Final trading day
- Nov 30, 2022
- Market cap at delisting
- $26.62M
- Shares outstanding
- 67.63M
- Final 52-week range
- $0.23 – $2.83
- Avg. volume (final 3 mo.)
- 1,322,704
- All-time high (split-adj.)
- $31.69 · Jun 2014
- All-time low (split-adj.)
- $0.23 · Oct 2022
- Return since IPO
- -97.3%
- Beta
- 1.58
- Book value / share
- $0.26
- Price / book
- 1.51
Applied Genetic annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2022 | $325.0K | -$68.9M | -$1.54 |
| FY2021 | $500.0K | -$57.8M | -$1.88 |
| FY2020 | $2.45M | -$45.9M | -$2.17 |
| FY2019 | $41.69M | -$2.0M | -$0.11 |
| FY2018 | $24.19M | -$21.3M | -$1.19 |
Last five fiscal years reported before the delisting; fiscal year ending June. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Applied Genetic
Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Phase 1/2 clinical trials; and achromatopsia that is in Phase 1/2 clinical trials. It is also developing an optogenetic product candidate to treat advanced retinal disease. In addition, the company has initiated one preclinical program in otology; preclinical program in dry age-related macular degeneration; and two preclinical programs in targeting central nervous system disorders, including frontotemporal dementia and amyotrophic lateral sclerosis. It has collaboration agreements with University of Florida; Bionic Sight, Inc.; and Otonomy, Inc. The company was incorporated in 1999 and is headquartered in Alachua, Florida.
Applied Genetic stock FAQ
What happened to Applied Genetic stock?
Applied Genetic stock was delisted from the Nasdaq. Its final close was $0.39 on November 30, 2022.
Is AGTC stock still trading?
No. AGTC was delisted from the Nasdaq in November 2022 and no longer trades on a U.S. exchange.
What was the last price of AGTC stock?
AGTC closed at $0.39 on its final trading day, November 30, 2022, for a market value of about $26.62M.
What were Applied Genetic's revenue and earnings in its last full fiscal year?
Applied Genetic reported revenue of $325.0K and net income of -$68.9M in fiscal 2022, its last full year as a public company.
When did Applied Genetic go public?
Applied Genetic stock began trading on March 27, 2014.